ArticleBioMed research international2021
Comprehensive Analysis of CD163 as a Prognostic Biomarker and Associated with Immune Infiltration in Glioblastoma Multiforme.
Article in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- Identifying survival subtypes with autoencoder using multiple types of high-dimensional genomic data from studies of glioblastoma multiforme.Briefings in bioinformatics · 2025Article
- Review
- Microglia and brain macrophages are differentially associated with tumor necrosis in glioblastoma: A link to tumor progression.Oncology research · 2025Article
- An immune-related gene pair signature predicts the prognosis and immunotherapeutic response in glioblastoma.Heliyon · 2024Article
- Optical microscopy and transcriptomics reveal the origins of fluorescence in glioma surgery.Nature biomedical engineering · 2024Article
- Localization of protoporphyrin IX during glioma-resection surgery via paired stimulated Raman histology and fluorescence microscopy.Nature biomedical engineering · 2024Article
- In Silico Analysis of the Correlation of KIF2C with Prognosis and Immune Infiltration in Glioma.Computational and mathematical methods in medicine · 2022Article
- Screening seven hub genes associated with prognosis and immune infiltration in glioblastoma.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma multiforme (GBM) is the most common and aggressive primary malignancy in adults with high aggression. The prognosis of GBM patients is poor. There is a critical need for novel biomarkers for the prognosis and therapy of GBM.
methodsDifferentially expressed genes (DEGs) in GBM were screened using TCGA cohort. Univariate and multivariate Cox regression analyses were performed on DEGs to identify the optimal prognosis-related genes. qRT-PCR was performed to verify the result.
resultsA total of 5216 DEGs, including 2785 upregulated and 2458 downregulated genes, were obtained. Enrichment analysis revealed that these DEGs were mainly involved in the p53 signaling pathway and cell cycle, immune response, and MAPK signaling pathways. Moreover, the top 50 DEGs were associated with drug resistance or drug sensitivity. Prognosis analysis revealed that GBM patients with a high expression of CD163 and CHI3L2 had a poor overall survival, prognosis-free survival, and disease-specific survival. The univariate and multivariate analyses revealed that CD163 and age were independent factors affecting the prognosis of GBM patients. A validation study revealed that CD163 was upregulated in GBM tissues and associated with poor overall survival. Moreover, further analysis revealed that CD163 showed significant correlation with immune cells, immune biomarkers, chemokines, and chemokine receptors. We also identified several CD163-associated kinase, miRNA, and transcription factor targets in GBM, including LCK, miR-483, and ELF1.
conclusionsIn conclusion, our study suggested CD163 as a prognostic biomarker and associated it with immune infiltration in GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.